

---

## Coala Life - Refilled growth capital

Redeye updates its estimates and valuation following Coala Life's recent rights issue, securing cSEK55m in growth capital and resulting in a 75% dilution for non-participating shareholders. CEO Dan Pitulia continues to demonstrate his commitment by investing SEK7m in the rights issue. Our revised estimates reflect the recent development in patient ramp-up for remote monitoring (PRM) and the announced cost-saving program. In our updated valuation, we also factor in an anticipated cash injection of SEK12m from the warrants due in Q2 2024 -our new Base case is SEK0.12 (SEK1.3) per share.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Coala Life - Refilled growth capital](#)